NCT07903493RecruitingPhase 1
Phase Ia Study of MST-931 in Healthy Adult Subjects
A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 18 Oct 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT07903493
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 32
- From 30 Nov 2026 to the primary completion date, 30 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects who meet any of the following criteria will be excluded from study entry
- Hypersensitivity to the Investigational Medicinal Product (IMP) or any of its components, to biological agents, or prior history of severe drug hypersensitivity reactions.
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, immunologic, dermatologic, psychiatric or neurological disease, or other significant clinical findings within 3 months before screening.
- History of malignancy within 5 years prior to screening, with the exception of patients with a negligible risk of metastases or death and/or treated with expected curative outcome.
- Family history of premature Coronary Heart Disease.
- Pregnant or Breastfeeding subject, women with positive pregnancy test (hCG).
- Unlikely to comply with the clinical study protocol.
Who the study is looking for
- Subjects must meet the following criteria to be eligible for study entry:
- Healthy male or female subjects age ≥ 18 and ≤ 55 years.
- Body Mass Index (BMI) ≥ 18 and ≤ 32 kg/m².
- Normal ECG, blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not clinically significant.
- Signed Informed consent form for participation in the study.
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Q-Pharm Pty Ltd Coordinator of this site? Confirm its status | Herston | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.